BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference
- Presentation available September 11, 2023 on BGBIO website - BERGEN, Norway, September 11, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for Non-Small Cell Lung Cancer (NSCLC), announced today that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference held in New York City, September 11-13, 2023. Chief Executive Officer Martin Olin will provide an update on BerGenBio including a review of clinical data substantiating the role of selective AXL